hrp0086fc4.1 | Pathophysiology of Obesity | ESPE2016

Contribution of Rare CNVs and Point Mutations to the Etiology of Severe Early-onset Obesity

Serra-Juhe Clara , Martos-Moreno Gabriel A , Bou Francesc , Flores Raquel , Rodriguez-Santiago Benjamin , Gonzalez Juan R , Argente Jesus , Perez-Jurado Luis A

Background: Studies aimed at elucidating the pathophysiology of obesity consistently describe it as a highly heterogeneous disorder at both clinical and molecular level. Despite rare monogenic forms and several regions of susceptibility have been defined, the genetic causes underlying the disease remain largely unknown.Objective and hypotheses: We aimed to identify novel genetic abnormalities in a cohort of Spanish children with severe non-syndromic earl...

hrp0092p1-274 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (1) | ESPE2019

Quality of Life in Chilean Transgender Children, Adolescents, and Their Parents

Mendoza Carolina , Martínez-Aguayo Alejandro , Flores Mónica , Morales Cristobal

Background: Quality of life (QOL) includes physical, psychological and social aspects. Transgender (TG) children undergo problems in school and with family, friends, and social relationships. These adverse effects on physical and psychosocial health can impair their quality of life.Objective and Methods: This study aims to assess health-related quality of life (HRQOL), using the KIDSCREEN-52 questionnaire (Spanish versio...

hrp0082p2-d3-314 | Bone (2) | ESPE2014

Early Calcinosis Cutis, Short Stature and Brachydactyly: a Case Evolution

Riano-Galan Isolina , Rodriguez-Dehli Cristina , Huidobro-Fernandez Belen , Alvarez M Victoria , Flores Silvia Avila , Toral Joaquin Fernandez

Background: Subcutaneous calcification is a rare clinical symptom in infancy. Progressive evolution and association with brachydactyly could be indicators of Albright hereditary osteodystrophy (AHO). In clinical practice, AHO is difficult to diagnose because of clinical heterogeneity. Typical features of AHO without any evidence of hormone resistance are termed pseudopseudohypoparathyroidism (PPHP; OMIM 612463).Case report: Male patient referred to study...

hrp0084p2-367 | Fat | ESPE2015

Residual Excess Weight Difference Between BMI 35–40 and Over 40 After Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Midterm Outcomes

Linares Jeannette , Villagran Rodrigo , Gallardo Michael , Garcia Isabela , Araya Sofia , Flores Carlos , Cariaga Mario , Fuentes Paulina , Yanez Marisol

Background: Severe obesity among adolescents is increasing worldwide. Bariatric surgery is a controversial subject in this group of age, surgical timing is even more controversial. Patterns of surgical weight loss could be different between patients with greater excess weight, perhaps with less promising results.Objective and hypotheses: To compare anthropometric outcomes among adolescents with BMI 35–40 and over 40, underwent laparoscopic sleeve ga...

hrp0095p1-154 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Reference values in pelvic ultrasonography for a Spanish population of healthy girls between 6 and 12 years old

Corripio Raquel , Villalobos Marisa , Patricia Beltrán-Salazar Viviana , Pérez Jacobo , Duran Carmina

Background: Pelvic ultrasonography (PUS) of the uterus and ovaries allows the diagnosis of changes in sexual development. However, the reference values used in Spain originate from old studies conducted in other countries.Objective: To determine reference uterine and ovarian measurements by PUS and according to pubertal status and bone age in a Spanish population of healthy girls aged between 6 and 12 years.<p class=...

hrp0095p2-207 | Multisystem Endocrine Disorders | ESPE2022

Bisphenol A (BPA): A Hidden Enemy

Grau Gema , Andrade Fernando , Vela Amaya , López Oceja Raquel , Rica Itxaso

Introduction: Endocrino disruptors (EDs) are substances that interfere with hormonal function. The long list of EDs includes multiple natural compounds and numerous synthetic chemicals such as bisphenol A (BPA). BPA is present in plastics used in common products (Packaging, bottles, toys, digital media, etc). Several studies have shown its ability to alter the regulation of developmentally relevant genes, inhibit the synthesis of sex hormones and induce the pr...

hrp0092p1-382 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Nutritional Requirements in Prader Willi Syndrome Children Treated with Growth Hormone Under Two Years of Age

Corripio Raquel , Franch Noemi , Couto Yolanda , Pérez Jacobo , Gabau Elisabeth , Capdevila Nuria , Rivera Josefa

Background: Prader Willi Syndrome (PWS) patients under treatment with growth hormone (GH) have a better body composition and cognitive performance than untreated patients. The 2013 guideline recommended to start this treatment as soon as possible, for that reason 14 toddlers have been included in our center. Classically a 25% decrease in the caloric intake of PWS patients has been recommended to avoid obesity. However, from clinical practice observation, w...

hrp0089p3-p108 | Diabetes &amp; Insulin P3 | ESPE2018

Psychosocial Risks, Comorbidities and Health Events During the Follow-up of Children and Adolescents with Type 1 Diabetes

Temboury Ma Carmen , Villamor Raquel , Hernandez Ma Belen , Lapena Sara , Lopez Cristina

Background: Psychosocial factors and health events are important for patients with chronic diseases such type 1 diabetes (TD1).Objective and hypotheses: The aim was to explore the psychosocial factors, health events and comorbidity found at diagnosis and during the follow up of children and adolescents with type 1 diabetes. Also to analyze the association between socioeconomic status and glycaemic control.Method: Medical charts of ...

hrp0089p1-p166 | Growth &amp; Syndromes P1 | ESPE2018

Safety and Effectiveness of Growth Hormone Treatment in Patients with Prader-Willi Syndrome under 2 Years of Age in a Reference Hospital

Corripio Raquel , Tubau Carla , Cahis Nuria , Perez Jacobo , Rivera Josefa , Gabau Elisabeth

Introduction: Growth hormone (GH) treatment was approved in 2000 for patients with Prader-Willi syndrome (PWS). The main reason for its use was the improvement in body composition. As a result of 2 fatal episodes, it was decided to initiate it from 2 years of age arbitrarily. Average age of real start: 4-6years. GH per se is not a risk factor for mortality in PWS. The 2013 guideline recommends to star it as soon as possible, preferably under 2 years of age, when obesity is est...

hrp0089p2-p245 | Growth &amp; Syndromes P2 | ESPE2018

Clinical Review of Seven Patients Affected with 49,XXXXY Syndrome

Sanchez Jacobo Perez , Collado Raquel Corripio , Escofet Concepcion , Brun Carme , Gabau Elisabeth

Introduction: 49,XXXXY polysomy incidence is about 1 per 85000 to 100000 male births. As a rare condition with medical problems affecting different systems it should be evaluated under a multidisciplinary approach. We have reviewed the clinical characteristics of patients with this anomaly from all the country who contacted the program for evaluation.Methods: In 2016 we started a multidisciplinary program for the care of patients with sex chromosomal ane...